Skip to main content
Top
Published in: Supportive Care in Cancer 4/2013

01-04-2013 | Original Article

Prevalence, predictors, and prognostic impact of fatigue among Brazilian outpatients with advanced cancers

Authors: Carlos Eduardo Paiva, Bianca Sakamoto Ribeiro Paiva

Published in: Supportive Care in Cancer | Issue 4/2013

Login to get access

Abstract

Purposes

The purposes of this study are to evaluate the impact of cancer-related fatigue (CRF) on quality of life (QoL), and to identify its clinical predictors. In addition, the authors investigated the prognostic impact of CRF and its relationship with the inflammatory marker C-reactive protein.

Method

Data regarding patient characteristics, symptom scores, and QoL indices were collected at the initial evaluation. At the same time, blood samples were collected in order to evaluate some laboratorial markers. Patients were followed by telephone interviews every 15 days until death. CRF was defined as ≥66.67 points on EORTC QLQ-C30 fatigue subscale.

Results

The examined patients had a median age of 61 years (range, 21–86 years) and 50.7 % were male. Median Karnofsky performance score (KPS) was 75.5 (SD, 15.1). The prevalence of CRF was 25 % (55 out of 221). Overall, patients with CRF presented higher symptom burden and also worst QoL scores. The following variables were independently associated with CRF: nausea (OR 1.22, p = 0.009), dyspnea (OR 1.33, p = 0.002), KPS (OR 0.96, p = 0.009), body mass index (OR 0.93, p = 0.046), and C-reactive protein (OR 1.08, p = 0.004). The median overall survival (OS) was lower in CRF patients (p < 0.0001). Only KPS (HR = 0.96, p < 0.001) and C-reactive protein (HR = 1.07, p < 0.001) were independent prognostic factors for OS.

Conclusions

Advanced cancer patients (ACP) with CRF had a higher burden of symptoms and impaired QoL. Our findings support the hypothesis that chronic inflammatory state (CIS) could play a role in the pathogenesis of fatigue in ACP. Moreover, CIS seems to have greater prognostic impact than the associated fatigue.
Literature
1.
go back to reference Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D, Jacobsen PB, Syrjala KL, Von Roenn JH, Cella D (2008) Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw 6(5):448–455PubMed Butt Z, Rosenbloom SK, Abernethy AP, Beaumont JL, Paul D, Hampton D, Jacobsen PB, Syrjala KL, Von Roenn JH, Cella D (2008) Fatigue is the most important symptom for advanced cancer patients who have had chemotherapy. J Natl Compr Canc Netw 6(5):448–455PubMed
3.
go back to reference Cavalli Kluthcovsky AC, Urbanetz AA, de Carvalho DS, Pereira Maluf EM, Schlickmann Sylvestre GC, Bonatto Hatschbach SB (2012) Fatigue after treatment in breast cancer survivors: prevalence, determinants and impact on health-related quality of life. Support Care Cancer 20(8):1901–1909CrossRef Cavalli Kluthcovsky AC, Urbanetz AA, de Carvalho DS, Pereira Maluf EM, Schlickmann Sylvestre GC, Bonatto Hatschbach SB (2012) Fatigue after treatment in breast cancer survivors: prevalence, determinants and impact on health-related quality of life. Support Care Cancer 20(8):1901–1909CrossRef
4.
go back to reference Cheng KK, Lee DT (2011) Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit Rev Oncol Hematol 78(2):127–137PubMedCrossRef Cheng KK, Lee DT (2011) Effects of pain, fatigue, insomnia, and mood disturbance on functional status and quality of life of elderly patients with cancer. Crit Rev Oncol Hematol 78(2):127–137PubMedCrossRef
5.
go back to reference Kawaguchi T, Iwase S, Koinuma M, Onodera Y, Takeuchi H, Umeda M, Matsunaga T, Unezaki S, Nagumo Y (2012) Determinants affecting quality of life: implications for pharmacist counseling for patients with breast cancer in Japan. Biol Pharm Bull 35(1):59–64PubMedCrossRef Kawaguchi T, Iwase S, Koinuma M, Onodera Y, Takeuchi H, Umeda M, Matsunaga T, Unezaki S, Nagumo Y (2012) Determinants affecting quality of life: implications for pharmacist counseling for patients with breast cancer in Japan. Biol Pharm Bull 35(1):59–64PubMedCrossRef
6.
go back to reference Gray NM, Hall SJ, Browne S, Macleod U, Mitchell E, Lee AJ, Johnston M, Wyke S, Samuel L, Weller D, Campbell NC (2011) Modifiable and fixed factors predicting quality of life in people with colorectal cancer. Br J Cancer 104(11):1697–1703PubMedCrossRef Gray NM, Hall SJ, Browne S, Macleod U, Mitchell E, Lee AJ, Johnston M, Wyke S, Samuel L, Weller D, Campbell NC (2011) Modifiable and fixed factors predicting quality of life in people with colorectal cancer. Br J Cancer 104(11):1697–1703PubMedCrossRef
7.
go back to reference Shi Q, Smith TG, Michonski JD, Stein KD, Kaw C, Cleeland CS (2011) Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society’s Studies of Cancer Survivors. Cancer 117(12):2779–2790PubMedCrossRef Shi Q, Smith TG, Michonski JD, Stein KD, Kaw C, Cleeland CS (2011) Symptom burden in cancer survivors 1 year after diagnosis: a report from the American Cancer Society’s Studies of Cancer Survivors. Cancer 117(12):2779–2790PubMedCrossRef
8.
go back to reference Scott JA, Lasch KE, Barsevick AM, Piault-Louis E (2011) Patients’ experiences with cancer-related fatigue: a review and synthesis of qualitative research. Oncol Nurs Forum 38(3):E191–E203PubMedCrossRef Scott JA, Lasch KE, Barsevick AM, Piault-Louis E (2011) Patients’ experiences with cancer-related fatigue: a review and synthesis of qualitative research. Oncol Nurs Forum 38(3):E191–E203PubMedCrossRef
9.
go back to reference Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5(5):353–360PubMedCrossRef Curt GA, Breitbart W, Cella D, Groopman JE, Horning SJ, Itri LM, Johnson DH, Miaskowski C, Scherr SL, Portenoy RK, Vogelzang NJ (2000) Impact of cancer-related fatigue on the lives of patients: new findings from the Fatigue Coalition. Oncologist 5(5):353–360PubMedCrossRef
10.
go back to reference Gupta D, Lis CG, Grutsch JF (2007) The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. J Pain Symptom Manage 34(1):40–47PubMedCrossRef Gupta D, Lis CG, Grutsch JF (2007) The relationship between cancer-related fatigue and patient satisfaction with quality of life in cancer. J Pain Symptom Manage 34(1):40–47PubMedCrossRef
11.
go back to reference Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition Semin Hematol 34(3 Suppl 2):4–12 Vogelzang NJ, Breitbart W, Cella D, Curt GA, Groopman JE, Horning SJ, Itri LM, Johnson DH, Scherr SL, Portenoy RK (1997) Patient, caregiver, and oncologist perceptions of cancer-related fatigue: results of a tripart assessment survey. The Fatigue Coalition Semin Hematol 34(3 Suppl 2):4–12
12.
go back to reference Oh HS, Seo WS (2011) Systematic review and meta-analysis of the correlates of cancer-related fatigue. Worldviews Evid Based Nurs 8(4):191–201PubMedCrossRef Oh HS, Seo WS (2011) Systematic review and meta-analysis of the correlates of cancer-related fatigue. Worldviews Evid Based Nurs 8(4):191–201PubMedCrossRef
13.
go back to reference Bower JE, Ganz PA, Aziz N, Olmstead R, Irwin MR, Cole SW (2007) Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav Immun 21(3):251–258PubMedCrossRef Bower JE, Ganz PA, Aziz N, Olmstead R, Irwin MR, Cole SW (2007) Inflammatory responses to psychological stress in fatigued breast cancer survivors: relationship to glucocorticoids. Brain Behav Immun 21(3):251–258PubMedCrossRef
14.
go back to reference Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE (2007) The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 21(4):413–427PubMedCrossRef Schubert C, Hong S, Natarajan L, Mills PJ, Dimsdale JE (2007) The association between fatigue and inflammatory marker levels in cancer patients: a quantitative review. Brain Behav Immun 21(4):413–427PubMedCrossRef
15.
go back to reference Jager A, Sleijfer S, van der Rijt CC (2008) The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator? Eur J Cancer 44(2):175–181PubMedCrossRef Jager A, Sleijfer S, van der Rijt CC (2008) The pathogenesis of cancer related fatigue: could increased activity of pro-inflammatory cytokines be the common denominator? Eur J Cancer 44(2):175–181PubMedCrossRef
16.
go back to reference Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW (2011) Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol 29(26):3517–3522PubMedCrossRef Bower JE, Ganz PA, Irwin MR, Kwan L, Breen EC, Cole SW (2011) Inflammation and behavioral symptoms after breast cancer treatment: do fatigue, depression, and sleep disturbance share a common underlying mechanism? J Clin Oncol 29(26):3517–3522PubMedCrossRef
17.
go back to reference Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMed Bruera E, Kuehn N, Miller MJ, Selmser P, Macmillan K (1991) The Edmonton Symptom Assessment System (ESAS): a simple method for the assessment of palliative care patients. J Palliat Care 7(2):6–9PubMed
18.
go back to reference Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton Symptom Assessment Scale. Cancer 88(9):2164–2171PubMedCrossRef Chang VT, Hwang SS, Feuerman M (2000) Validation of the Edmonton Symptom Assessment Scale. Cancer 88(9):2164–2171PubMedCrossRef
19.
go back to reference Franceschini J, Jardim JR, Fernandes AL, Jamnik S, Santoro IL (2010) Reproducibility of the Brazilian Portuguese version of the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire used in conjunction with its lung cancer-specific module. J Bras Pneumol 36(5):595–602PubMedCrossRef Franceschini J, Jardim JR, Fernandes AL, Jamnik S, Santoro IL (2010) Reproducibility of the Brazilian Portuguese version of the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire used in conjunction with its lung cancer-specific module. J Bras Pneumol 36(5):595–602PubMedCrossRef
20.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC et al (1993) The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376PubMedCrossRef
21.
go back to reference Minton O, Stone P (2009) A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 20(1):17–25PubMedCrossRef Minton O, Stone P (2009) A systematic review of the scales used for the measurement of cancer-related fatigue (CRF). Ann Oncol 20(1):17–25PubMedCrossRef
22.
go back to reference Stone P, Richards M, A’Hern R, Hardy J (2000) A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11(5):561–567PubMedCrossRef Stone P, Richards M, A’Hern R, Hardy J (2000) A study to investigate the prevalence, severity and correlates of fatigue among patients with cancer in comparison with a control group of volunteers without cancer. Ann Oncol 11(5):561–567PubMedCrossRef
23.
go back to reference Minton O, Strasser F, Radbruch L, Stone P (2012) Identification of factors associated with fatigue in advanced cancer: a subset analysis of the European palliative care research collaborative computerized symptom assessment data set. J Pain Symptom Manage 43(2):226–235PubMedCrossRef Minton O, Strasser F, Radbruch L, Stone P (2012) Identification of factors associated with fatigue in advanced cancer: a subset analysis of the European palliative care research collaborative computerized symptom assessment data set. J Pain Symptom Manage 43(2):226–235PubMedCrossRef
24.
go back to reference Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, Belin TR (2006) Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106(4):751–758PubMedCrossRef Bower JE, Ganz PA, Desmond KA, Bernaards C, Rowland JH, Meyerowitz BE, Belin TR (2006) Fatigue in long-term breast carcinoma survivors: a longitudinal investigation. Cancer 106(4):751–758PubMedCrossRef
25.
go back to reference Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR (2007) Cancer-related fatigue: the scale of the problem. Oncologist 12(Suppl 1):4–10PubMedCrossRef Hofman M, Ryan JL, Figueroa-Moseley CD, Jean-Pierre P, Morrow GR (2007) Cancer-related fatigue: the scale of the problem. Oncologist 12(Suppl 1):4–10PubMedCrossRef
26.
go back to reference Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J (2004) Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 32:40–50PubMedCrossRef Lawrence DP, Kupelnick B, Miller K, Devine D, Lau J (2004) Evidence report on the occurrence, assessment, and treatment of fatigue in cancer patients. J Natl Cancer Inst Monogr 32:40–50PubMedCrossRef
27.
go back to reference Storey DJ, Waters RA, Hibberd CJ, Rush RW, Cargill AT, Wall LR, Fallon MT, Strong VA, Walker J, Sharpe M (2007) Clinically relevant fatigue in cancer outpatients: the Edinburgh Cancer Centre symptom study. Ann Oncol 18(11):1861–1869PubMedCrossRef Storey DJ, Waters RA, Hibberd CJ, Rush RW, Cargill AT, Wall LR, Fallon MT, Strong VA, Walker J, Sharpe M (2007) Clinically relevant fatigue in cancer outpatients: the Edinburgh Cancer Centre symptom study. Ann Oncol 18(11):1861–1869PubMedCrossRef
28.
go back to reference Bruera E (2010) Cancer-related fatigue: a multidimensional syndrome. J Support Oncol 8(4):175–176PubMed Bruera E (2010) Cancer-related fatigue: a multidimensional syndrome. J Support Oncol 8(4):175–176PubMed
29.
go back to reference Barsevick A, Frost M, Zwinderman A, Hall P, Halyard M (2010) I’m so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res 19(10):1419–1427PubMedCrossRef Barsevick A, Frost M, Zwinderman A, Hall P, Halyard M (2010) I’m so tired: biological and genetic mechanisms of cancer-related fatigue. Qual Life Res 19(10):1419–1427PubMedCrossRef
30.
go back to reference Barbera L, Seow H, Howell D, Sutradhar R, Earle C, Liu Y, Stitt A, Husain A, Sussman J, Dudgeon D (2010) Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer 116(24):5767–5776PubMedCrossRef Barbera L, Seow H, Howell D, Sutradhar R, Earle C, Liu Y, Stitt A, Husain A, Sussman J, Dudgeon D (2010) Symptom burden and performance status in a population-based cohort of ambulatory cancer patients. Cancer 116(24):5767–5776PubMedCrossRef
31.
go back to reference Walsh D, Rybicki L (2006) Symptom clustering in advanced cancer. Support Care Cancer 14(8):831–836PubMedCrossRef Walsh D, Rybicki L (2006) Symptom clustering in advanced cancer. Support Care Cancer 14(8):831–836PubMedCrossRef
33.
go back to reference Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL, Morais JA (2010) Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachexia Sarcopenia Muscle 1(2):177–185PubMedCrossRef Kilgour RD, Vigano A, Trutschnigg B, Hornby L, Lucar E, Bacon SL, Morais JA (2010) Cancer-related fatigue: the impact of skeletal muscle mass and strength in patients with advanced cancer. J Cachexia Sarcopenia Muscle 1(2):177–185PubMedCrossRef
34.
go back to reference Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87(3):264–267PubMedCrossRef Scott HR, McMillan DC, Forrest LM, Brown DJ, McArdle CS, Milroy R (2002) The systemic inflammatory response, weight loss, performance status and survival in patients with inoperable non-small cell lung cancer. Br J Cancer 87(3):264–267PubMedCrossRef
35.
go back to reference Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Cho SH, Chung IJ (2011) Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer 11:489PubMedCrossRef Hwang JE, Kim HN, Kim DE, Choi HJ, Jung SH, Shim HJ, Bae WK, Hwang EC, Cho SH, Chung IJ (2011) Prognostic significance of a systemic inflammatory response in patients receiving first-line palliative chemotherapy for recurred or metastatic gastric cancer. BMC Cancer 11:489PubMedCrossRef
36.
go back to reference Gueron G, De Siervi A, Vazquez E (2012) Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis 15(3):213–221PubMedCrossRef Gueron G, De Siervi A, Vazquez E (2012) Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis 15(3):213–221PubMedCrossRef
37.
go back to reference Saligan LN, Kim HS (2012) A systematic review of the association between immunogenomic markers and cancer-related fatigue. Brain Behav Immun 26(6):830–848PubMedCrossRef Saligan LN, Kim HS (2012) A systematic review of the association between immunogenomic markers and cancer-related fatigue. Brain Behav Immun 26(6):830–848PubMedCrossRef
38.
go back to reference Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS (2012) Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 26(5):699–705PubMedCrossRef Wang XS, Williams LA, Krishnan S, Liao Z, Liu P, Mao L, Shi Q, Mobley GM, Woodruff JF, Cleeland CS (2012) Serum sTNF-R1, IL-6, and the development of fatigue in patients with gastrointestinal cancer undergoing chemoradiation therapy. Brain Behav Immun 26(5):699–705PubMedCrossRef
39.
go back to reference Zimmerman MA, Selzman CH, Cothren C, Sorensen AC, Raeburn CD, Harken AH (2003) Diagnostic implications of C-reactive protein. Arch Surg 138(2):220–224PubMedCrossRef Zimmerman MA, Selzman CH, Cothren C, Sorensen AC, Raeburn CD, Harken AH (2003) Diagnostic implications of C-reactive protein. Arch Surg 138(2):220–224PubMedCrossRef
40.
go back to reference Orre IJ, Reinertsen KV, Aukrust P, Dahl AA, Fossa SD, Ueland T, Murison R (2011) Higher levels of fatigue are associated with higher CRP levels in disease-free breast cancer survivors. J Psychosom Res 71(3):136–141PubMedCrossRef Orre IJ, Reinertsen KV, Aukrust P, Dahl AA, Fossa SD, Ueland T, Murison R (2011) Higher levels of fatigue are associated with higher CRP levels in disease-free breast cancer survivors. J Psychosom Res 71(3):136–141PubMedCrossRef
41.
go back to reference Alexander S, Minton O, Andrews P, Stone P (2009) A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome. Eur J Cancer 45(3):384–392PubMedCrossRef Alexander S, Minton O, Andrews P, Stone P (2009) A comparison of the characteristics of disease-free breast cancer survivors with or without cancer-related fatigue syndrome. Eur J Cancer 45(3):384–392PubMedCrossRef
43.
go back to reference Ehrsson YT, Hellstrom PM, Brismar K, Sharp L, Langius-Eklof A, Laurell G (2010) Explorative study on the predictive value of systematic inflammatory and metabolic markers on weight loss in head and neck cancer patients undergoing radiotherapy. Support Care Cancer 18(11):1385–1391. doi:10.1007/s00520-009-0758-4 PubMedCrossRef Ehrsson YT, Hellstrom PM, Brismar K, Sharp L, Langius-Eklof A, Laurell G (2010) Explorative study on the predictive value of systematic inflammatory and metabolic markers on weight loss in head and neck cancer patients undergoing radiotherapy. Support Care Cancer 18(11):1385–1391. doi:10.​1007/​s00520-009-0758-4 PubMedCrossRef
44.
45.
go back to reference Mills PJ, Ancoli-Israel S, Parker B, Natarajan L, Hong S, Jain S, Sadler GR, von Kanel R (2008) Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer. Brain Behav Immun 22(1):98–104PubMedCrossRef Mills PJ, Ancoli-Israel S, Parker B, Natarajan L, Hong S, Jain S, Sadler GR, von Kanel R (2008) Predictors of inflammation in response to anthracycline-based chemotherapy for breast cancer. Brain Behav Immun 22(1):98–104PubMedCrossRef
Metadata
Title
Prevalence, predictors, and prognostic impact of fatigue among Brazilian outpatients with advanced cancers
Authors
Carlos Eduardo Paiva
Bianca Sakamoto Ribeiro Paiva
Publication date
01-04-2013
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 4/2013
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-012-1625-2

Other articles of this Issue 4/2013

Supportive Care in Cancer 4/2013 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine